The new prescription drug user fee agreement would reserve funds for hiring and retaining drug-review staff, a direct response to the layoffs that hollowed out the FDA’s review capacity this year. According to Endpoints News, the deal sets aside specific money to rehire reviewers lost in the spring cuts, rather than simply folding headcount into general operating funds.
The staffing context is what makes the provision notable. The FDA lost a substantial number of staff in April, including negotiators for the user-fee talks themselves, and industry has been pressing the agency on whether it can restaff reviewers and other PDUFA-funded positions. Meeting minutes from the January 2026 FDA-industry finance subgroup show the agency committing to restaff as quickly as possible while industry pressed for tracking and reporting on how the money would be secured. PharmaVoice’s coverage of the draft agreement similarly flagged the reserved hiring funds, while noting that money alone does not guarantee the agency can fill the positions.
The PDUFA VIII agreement, which must be authorized by Congress before the current user-fee authority expires at the end of September 2027, sets performance objectives and fee structures for fiscal years 2028 through 2032. Public comment on the PDUFA agreement runs to October 16, and Congress takes up reauthorization in 2027. For drug developers, review timelines depend on the reviewers being there; this provision is the first tangible attempt to restore the capacity that collapsed this spring, even if hiring in a tight scientific labor market remains the hard part.
This story is graded C because the specific deal terms come from a single trade report and were not independently verified against the agreement text.